Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$1.28
$0.75
$26.18
$7.26M1.27811,695 shs119,800 shs
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$4.60
-6.5%
$0.96
$4.30
$658.60
$37.30M6.0671,389 shs136,053 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.18
-5.3%
$0.16
$0.12
$4.55
$1.50M-0.141.25 million shs34,359 shs
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
$1.43
+5.3%
$1.34
$0.19
$2.65
$25.17M3.081.39 million shs5,776 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-6.50%+1,110.53%+651.63%+28.13%-99.54%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-5.26%+5.88%+28.57%-2.70%-90.58%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
+5.33%-3.38%+19.18%-5.30%-68.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.1405 of 5 stars
3.54.00.00.02.10.00.6
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
2.002 of 5 stars
3.50.00.00.02.60.01.3
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00
N/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$10,952.00237,986.96% Upside
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$20.0011,011.11% Upside
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$4.76M0.00N/AN/A($1.26) per share0.00
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M11.99N/AN/A$3.26 per share1.41
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/A$0.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/A
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/A

Latest BPTH, HILS, ADMP, and APVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$4.21-$4.39-$0.18-$4.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/A
0.23
0.19
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
1.72
1.72
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/A
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
38.55%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
13.36%

Insider Ownership

CompanyInsider Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
1.30%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.01%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
30.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
119.36 million9.24 millionOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
508.11 million1.46 millionNot Optionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
108.31 million5.73 millionOptionable
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
117.60 million12.28 millionNot Optionable

Recent News About These Companies

Hill & Smith PLC HILS
Kiromic BioPharma Inc Ordinary Shares KRBP
NMTRQ 9 Meters Biopharma, Inc.
HILS - Hillstream BioPharma, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamis Pharmaceuticals stock logo

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$4.60 -0.32 (-6.50%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$4.56 -0.04 (-0.98%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.18 -0.01 (-5.26%)
As of 05/28/2025 03:49 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Hillstream BioPharma stock logo

Hillstream BioPharma NASDAQ:HILS

$1.43 +0.07 (+5.33%)
As of 05/27/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.